JP MORGAN/CALL/EDWARDS LIFESCIENCES/120/0.1/17.01.25 | Real-time Bid/Ask 18:53:58 07/06/2024 BST | ||
| 0.091 EUR / 0.11 EUR | +23.17% |
|
| Current month | -11.83% | ||
| 1 month | -10.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 0.089 | +8.54% |
| 06/06/24 | 0.082 | -9.89% |
| 05/06/24 | 0.091 | -4.21% |
| 04/06/24 | 0.095 | +10.47% |
| 03/06/24 | 0.086 | -7.53% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 09:12 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JL1J22 |
| ISIN | DE000JL1J220 |
| Date issued | 06/04/2023 |
| Strike | 120 $ |
| Maturity | 17/01/2025 (224 Days) |
| Parity | 10 : 1 |
| Emission price | 0.45 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.75 € |
|---|---|
| Lowest since issue | 0.047 € |
| Spread | 0.02 € |
| Spread % | 18.18% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
87.68
USD
Average target price
96.31
USD
Spread / Average Target
+9.84%
- Stock Market
- Warrants
- Warrant